MindMed

MindMed Stock Rockets on Breakthrough LSD Anxiety Data – Analysts Eye 100% Upside

Stock Soars on Catalyst News MindMed’s stock has skyrocketed in recent weeks. After languishing in the single digits, MNMD climbed above $12 in late September and spiked to $13.09 on Oct. 14, its highest level in over a year ts2.tech marketbeat.com. The surge has pushed the stock roughly +68% year-to-date ts2.tech. Heavy trading volume accompanied the rise, as investors reacted to the latest clinical and regulatory news. (By Oct 17, shares were trading around $13.60 stockinvest.us.) This rally has made MindMed one of the year’s best-performing small-cap biotechs. Wall Street sentiment is strongly positive: MarketBeat notes MNMD has seven analyst

18 October 2025

MindMed Stock Skyrockets on Psychedelic Breakthroughs – What’s Driving the MNMD Surge?

MindMed Stock Soars 15% to 52-Week High on Psychedelic Breakthrough – What’s Next for MNMD?

Key Facts – October 18, 2025 MNMD Stock Rallies to New Highs on Heavy Volume MindMed’s stock has been on fire, vastly outperforming the broader market in recent weeks. Shares rocketed to a 52-week high of $13.09 on October 14, closing that day at $12.58 on unusually heavy volume ts2.tech. After a brief mid-week pullback on profit-taking (shares dipped ~4% intraday on Oct. 16) ts2.tech, MNMD roared back by week’s end – closing at $13.65 on Friday, Oct. 17, a one-day gain of +14.6% investing.com. This rally has propelled MindMed to roughly +68% YTD returns ts2.tech, a remarkable run fueled

18 October 2025

Biotechnology · Financial News · Investing · NASDAQ:CMPS · NASDAQ:MNMD · NYSE:ABBV · Psychedelics · Stock Market

MindMed Stock Skyrockets on Psychedelic Breakthroughs – What’s Driving the MNMD Surge?

Stock Soars to 52-Week High on Investor Hype MindMed’s stock has been on fire in recent weeks, vastly outperforming the broader market. Shares rocketed to a 52-week high of $13.09 on October 14, closing that day at $12.58 with unusually heavy trading volume marketbeat.com. Just a couple of weeks earlier, on September 29, MNMD spiked 12.8% in a single session, hitting ~$12.04 by day’s end allpennystocks.com. These sharp gains have propelled MindMed to roughly +68% year-to-date returns finance.yahoo.com, a remarkable run driven by excitement over its clinical progress. Investor sentiment is clearly bullish. The stock’s rally has been supported by

18 October 2025

Biotechnology · Financial News · Investing · NASDAQ:MNMD · Psychedelics · Stock Market